Clinical trial
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects…
NCT00392171 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00392171 |
|---|---|
| Title | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) |
| Official title | The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma, Astrocytoma, Oligodendroglioma, Glioblastoma |
| Intervention type | Drug |
| Interventions | Temozolomide |
| Enrollment | 120 |
| Start date | Jun 9, 2006 |
| Primary completion | Sep 15, 2009 |
| Completion | Sep 15, 2009 |
| First posted | Oct 25, 2006 |
| Last update posted | Jun 7, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: